**Table S4:** **Factors associated with progression free survival (PFS), time to treatment failure (TTF) and overall survival (OS) among patients using eribulin (choose those variables with *p*<0.1 into multivariate analysis), n=118, excluding those having eribulin as first line chemotherapy**

|  |  |  |  |
| --- | --- | --- | --- |
| Factors | PFS | TTF | OS |
| HR (95%CI) | HR (95%CI) | HR (95%CI) |
| Chemo-ADPT |  |  |  |
| 1st tertile (ref) | 1 | 1 | 1 |
| 2nd tertile | 0.47 (0.27-0.81) | 0.53 (0.33-0.85) | 0.38 (0.17 -0.82) |
| 3rd tertile | 0.58 (0.34-1.00) | 0.51 (0.32-0.82) | 0.40 (0.17 -0.82) |
| Number of metastatic sites (≥2 sites vs. <2 (ref)) | 1.54 (0.87-2.73) | - | - |
| Eribulin line of therapy (LL vs. EL (ref)) | - | - | 5.86 (1.41-24.36) |

Chemo-ADPT= average duration of prior chemotherapy treatment lines before initiation of eribulin; EL=early-line; LL=late-line